
MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer
Stage I Prostate CancerStage II Prostate CarcinomaThis phase II trial studies how well magnetic resonance (MR)-guided laser interstitial thermal therapy works in treating patients with prostate cancer. Laser therapy uses intense, narrow beams of light to cut and destroy tissue and may help treat prostate cancer

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
Uterine Cervical NeoplasmsEndometrial Neoplasms3 more[F-18] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone marrow will help maintain blood counts. This would impact chemotherapy administration.

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
Hormone Refractory Prostate CancerThe aim of this study is to evaluate efficacy and safety of Dovitinib(TKI258) in patients with castration resistant prostate cancer after failure of docetaxel-based chemotherapy. Further correlative study for metabolic response using PET image and change in serum fibroblast growth factor 23(FGF23) will be conducted.

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population
Prostate CancerOne month degarelix/comparator treatment for prostate cancer in Chinese population

Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
Prostate AdenocarcinomaRecurrent Prostate Carcinoma3 moreThis phase II trial studies how well itraconazole works in treating patients with biochemically relapsed prostate cancer. Itraconazole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide...
Prostate CancerThe goal of this clinical research study is to learn if adding the combination of abiraterone acetate and prednisone with or without enzalutamide to hormonal therapy can help to control prostate cancer when given before surgery. The safety of the drug combination will also be studied.

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone...
Prostate CancerThis is an open label study designed to examine the effects on concurrent administration of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone in subjects with symptomatic castrate resistant prostate cancer and with bone metastases, in both the pre- and post- chemotherapy setting. Both medications are approved by the US Food and Drug Administration for this indication.

F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer
Castration-resistant Prostate CancerUntil today no current diagnostic tool exists to identify an early objective response when patients with castration-resistant prostate cancer were treated by abiraterone acetate or enzalutamide. According to the Prostate Cancer Working Group, the investigators have to wait 12 weeks before the first evaluation. To know soon that the treatment is effective will be decisive for the oncologist, even more in palliative situation where second effects can't be imposed to patients. In post-docetaxel, the F-choline PET-CT could be used to assess the response of this new therapy. Moreover, the investigators suppose that we can assess an early stage if there is an objective therapeutic response, at 6 weeks of treatment, in order to avoid unnecessarily and expansive treatment. The aim of this study is to assess if it is possible to determine early (6 weeks of treatment)if a F-choline PET-CT could predict the response to abiraterone acetate or enzalutamide in post-docetaxel.

Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer
Prostate CancerThis research study provides a novel opportunity to examine the intra-prostatic tumour inhibitory effects of statins in men with prostate cancer undergoing surgery.

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic...
Prostate CancerThe purpose of this study is to evaluate the safety and pharmacokinetics (study of what the body does to a drug) of 1000 mg oral dose of abiraterone acetate and its major metabolite(s) with mild or moderate hepatic impairment and matched control Participants with normal hepatic function.